Agora Labs, an Italian healthtech company developing privacy-preserving clinical data infrastructure, has raised €4.3 million in a funding round led by venture capital firm P101 SGR. The round also included participation from the Mussetto family, owners of Infinite Five, a holding company active in marketing technology, data analytics and robotics.
Founded in 2022, Agora Labs develops technology that enables hospitals to use clinical data for medical and scientific research while maintaining control over patient information. The company is led by co-founder and CEO Davide Zaccagnini, a vascular surgeon and biomedical informatics specialist, with Fabio Giulietto serving as Chief Business Officer.
Its infrastructure uses dedicated computing nodes installed within healthcare facilities. These systems employ specialised large language models to structure and standardise clinical information, alongside data anonymisation technologies designed to protect patient privacy.
Through federated artificial intelligence and machine learning, the platform enables research organisations and pharmaceutical companies to conduct studies across participating institutions without requiring patient-level clinical records to leave their respective hospitals. It also supports the local training and validation of AI models.
According to P101, Agora Labs operates an international network of 50 healthcare facilities, including institutions associated with Harvard Medical School and San Raffaele Hospital in Milan. The company aims to expand this network to 100 facilities.
The new funding will support further expansion across Europe and the United States, as well as entry into additional markets in the Middle East and India. Agora Labs also plans to recruit approximately 20 technical and commercial professionals.
The company’s infrastructure is being used in research initiatives involving hospital pharmacy data and healthcare pathways in Italy. In Saudi Arabia, a separate project is combining genetic, clinical and radiological information to develop predictive models for complications associated with type 1 and type 2 diabetes.
The investment will support Agora Labs’ efforts to extend its healthcare data network and enable research collaborations across multiple institutions and geographies.
